The study focuses on people with Diabetes, a condition that can make infections more likely. All participants receive a routine Pneumovax 23 injection, which protects against many types of the bacteria that cause pneumonia. The trial examines whether adding a medication called liraglutide, which belongs to a group of drugs known as GLP-1 receptor agonists, can improve the body’s immune response to this vaccine.
The purpose of the study is to determine if starting the GLP-1 therapy enhances the protective effect of the pneumococcal vaccine. Participants are given the vaccine and then either begin treatment with the study medication or continue with usual care (some may receive a placebo). Blood samples are taken a short time after vaccination and again several months later to see how well the immune system has responded, while safety is checked through routine visits and questionnaires.
In simple terms, the researchers measure the level of IgG antibodies, which are proteins that help the body recognize and fight the bacteria. They also look at markers of inflammation (signs that the body is reacting to infection) and count certain immune cells to see if the medication changes their numbers or function. Any side effects or serious health problems related to infection are recorded throughout the study.
The Netherlands 
